玻璃体腔注射康柏西普联合黄斑区格栅样光凝治疗DME

目的:观察玻璃体腔注射康柏西普眼用注射液联合黄斑区格栅样光凝治疗糖尿病性黄斑水肿(diabetic macular edema,DME)的临床疗效.方法:对DME患者(40例40眼)随机分成试验组和对照组,每组各20例20眼.两组均实施一次黄斑区格栅样光凝治疗,试验组分别在第1次激光时及相隔45d后行玻璃体腔注射康柏西普治疗,比较两组患者激光术后45、90d的黄斑水肿消退情况及视力改变情况.结果:试验组术后45d黄斑厚度为293.90±12.94μm,对照组术后45d黄斑厚度为320.20±29.17μm,两组差异有统计学意义(P<0.05);试验组术后90d黄斑厚度为265.80±16.26μm,对照组术后90d黄斑厚度为290.15±12.23μm,两组差异有统计学意义(P<0.05);试验组术后45d最佳矫正视力为0.40±0.08,对照组术后45d最佳矫正视力为0.34±0.04,两组差异有统计学意义(P<0.05);试验组术后90d最佳矫正视力为0.46±0.09,对照组术后90d最佳矫正视力为0.37±0.06,两组差异有统计学意义(P<0.05).结论:玻璃体腔注射康柏西普联合格栅样光凝治疗DME较单纯黄斑区格栅样光凝组能明显提高视力,减轻黄斑水肿,对于延长两次玻璃体腔注射康柏西普间隔时间是否可以更为科学,仍需进一步研究.

Clinical effect of Conbercept intravitreal injection combined with macular grid laser photocoagulation on the treatment of diabetic macular edema

AIM: To investigate the clinical effect of conbercept intravitreal injection combined with macular grid laser photocoagulation on the treatment of diabetic macular edema(DME).METHODS: Forty patients (40 eyes) with diabetic macular edema were randomly divided into experimental group (20 cases) and control group (20 cases).Both groups received macular grid laser photocoagulation, and the experimental group combined with intravitreal injection of conbercept on the same day.At 45d later the experimental group received intravitreal injection of conbercept again.The central macular thickness (CMT) and best corrected visual acuity (BCVA) of the two groups were compared before and at 45 and 90d after treatments.RESULTS: At 45d after the treatment, the data of CMT between two groups was significant difference(experimental group: 293.90±12.94μm, control group: 320.20±29.17μm;P<0.05). At 90d after the treatment, the data of CMT between two groups was significant difference(experimental group: 265.80±16.26μm, control group: 290.15±12.23μm;P<0.05).At 45d after the treatment, the data of BCVA between two groups was significant difference(experimental group: 0.40±0.08, control group: 0.34± 0.04, P<0.05).At 90d after the treatment, the data of BCVA between two groups was significant difference(experimental group: 0.46±0.09;control group: 0.37±0.06;P<0.05).CONCLUSION: Conbercept intravitreal injection combined with macular grid laser photocoagulation on the treatment of DME is much better on improving visual acuity and reducing macular edema than the grid laser photocoagulation treatment alone.For extension of the time of Conbercept intravitreal injection can be more scientific or not, still needs further research.